Syncor in three year sole source deal with Kaiser:
This article was originally published in Clinica
Kaiser Permanente's newly-formed National Purchasing Organization has signed a three-year sole source contract with Syncor International for unit dose and bulk radiopharmaceuticals. The deal has a potential to exceed $15 million, according to Syncor. Radiopharmaceuticals are used in diagnostic imaging and therapy.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.